INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 204 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $0 | – | 50 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 50 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 50 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | – | 50 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 50 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 50 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $2,000 | 0.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $2,000 | -33.3% | 50 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $3,000 | -40.0% | 50 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $5,000 | +66.7% | 50 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $3,000 | 0.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $3,000 | -40.0% | 50 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $5,000 | +25.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $4,000 | -33.3% | 50 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $6,000 | +50.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $4,000 | +33.3% | 50 | 0.0% | 0.00% | +100.0% |
| Q1 2018 | $3,000 | +50.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $2,000 | 0.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,000 | -66.7% | 50 | 0.0% | 0.00% | -66.7% |
| Q2 2017 | $6,000 | +20.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $5,000 | 0.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $5,000 | -37.5% | 50 | 0.0% | 0.00% | -40.0% |
| Q3 2016 | $8,000 | +14.3% | 50 | 0.0% | 0.01% | +25.0% |
| Q2 2016 | $7,000 | +16.7% | 50 | 0.0% | 0.00% | +33.3% |
| Q1 2016 | $6,000 | -14.3% | 50 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $7,000 | -12.5% | 50 | 0.0% | 0.00% | -25.0% |
| Q3 2015 | $8,000 | -33.3% | 50 | 0.0% | 0.00% | -20.0% |
| Q2 2015 | $12,000 | -14.3% | 50 | 0.0% | 0.01% | -16.7% |
| Q1 2015 | $14,000 | -30.0% | 50 | -60.0% | 0.01% | -33.3% |
| Q4 2014 | $20,000 | -33.3% | 125 | 0.0% | 0.01% | -52.6% |
| Q3 2014 | $30,000 | -57.7% | 125 | -58.3% | 0.02% | -76.5% |
| Q2 2014 | $71,000 | – | 300 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WHITE SQUARE CAPITAL LLP | 65,500 | $7,117,000 | 11.05% |
| Ghost Tree Capital, LLC | 70,000 | $7,606,000 | 1.83% |
| Carmignac Gestion | 2,022,792 | $219,776,000 | 1.71% |
| Orbimed Advisors | 1,120,000 | $121,688,000 | 1.55% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 29,555 | $3,211,000 | 1.45% |
| Parametrica Management Ltd | 10,814 | $1,175,000 | 1.16% |
| BB BIOTECH AG | 255,719 | $27,784,000 | 1.03% |
| SECTORAL ASSET MANAGEMENT INC | 74,150 | $8,056,000 | 0.89% |
| ALTRINSIC GLOBAL ADVISORS LLC | 188,904 | $20,524,000 | 0.76% |
| FALCON POINT CAPITAL, LLC | 45,005 | $4,890,000 | 0.66% |